Loading in 2 Seconds...
Loading in 2 Seconds...
Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy. Investor Presentation Q1 2011 www.accesspharma.com. Safe Harbor Statement.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Rich Product Pipeline – Active Partnering Strategy
This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access's Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission.
These materials are not an offer to sell securities and are not soliciting an offer to buy securities.
For Additional Access Pharmaceuticals Information, Go to the Following
Publicly Available Resources:
at Access Pharmaceuticals
Access Pharmaceuticals, Inc.(ACCP.OB) – a drug delivery company with late-stage products for cancer, diabetes and hormone replacement. Several products are based on Access’ proprietary drug delivery platform technologies.
Two proprietary, drug-delivery platform technologies enable product development across multiple biotechnology sub-sectors: Cancer, Diabetes, Hormone, Fertility, etc..
Significant Medical Issue – Often Unrecognized, Undiagnosed and Undertreated
Large Unmet Medical Need – Commercially Launching in US, Europe and Far East
Indications: indicated for the management of pain and relief of pain…
Directions for use: Gargle and spit out.
Indications: dryness or dry mouth associated with various conditions
Directions for use: Swish and spit out.
Indications: “Magic mouthwash" prepared by pharmacists and used to treat mouth sores (oral mucositis)
Directions for use: Gargle and spit out
Indications: MuGard is indicated for the management of oral mucositis/ stomatitis
Directions for use:
… rinse may be expelled or swallowed … safe to swallow …
…recommended that patients purchase MuGard™prior to the commencement of cancer therapy ..
MuGard is recommended for preventative use
MuGard can be swallowed to coat lesions in throat
ACCP Remains On-track for Full-Scale North American MuGard Launch
to enhance absorption of large molecules
CobOral / CobaCyte Drug Delivery Platforms
Using The Body’s Own Vitamin B-12 Absorption System
To Enable and Enhance Delivery of Drugs
The “Trojan Horse” Delivery Vehicle
The nanoparticle coated
with Cobalamin (red)
binds to intrinsic factor (1),
which in turn binds to its
cell surface receptor (2).
The nanoparticle is
transported across the
cell (3), crosses the gut
wall and enters the
Nanopolymer “payload” can be
Insulin, growth hormone, EPO, etc.
Cobalamin Enhanced Nanopolymers – Enabling Oral Insulin
Multiple CobOral Formulation Agreements In Place
Clinically Relevant Glucose Lowering
Effect in Diabetic Rat Model
Multiple Collaborations Driving Enhanced Data Set;
Planning Initiation of Phase 1 Human Trial in Cobalamin Oral Insulin
Positioning ProLindac™ as a Replacement for Sanofi-Aventis’ Eloxatin
Represents a $3+ Billion Market Opportunity
DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background
Chelator releases platinum compound in low pH environment; e.g. tumor
Final Study Results – Safe and Active DACH Platinum Drug
for Leukemias and Lymphomas
Significant Clinical Data Available – Initiated Phase I/II study
at MD Anderson Cancer Center
Active Business Development Effort; Securing Partnerships and
Collaborations to Enhance Value and Share Costs
Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.
Strong Board of Directors with Relevant Experience
Common shares outstanding 19.2 million shares
Common under preferred shares 11.7 million shares
Total common shares 30.9 million shares
Significant News Flow Anticipated in 2011 and 2012
ACCP – An Undervalued Investment Opportunity